<DOC>
	<DOC>NCT00162071</DOC>
	<brief_summary>The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.</brief_summary>
	<brief_title>A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>18 years of age or older Have known or suspected heart disease Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days. Weigh between 88 and 250 lbs. Allergic reaction to Technetium Tc99m Sestamibi or any of its components History of asthma or lung disease Ingestion of caffeinated substances within 12 hours prior to the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>